EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Foghorn Therapeutics's Enterprise Value is $119.69 Mil.
Foghorn Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-103.89 Mil. Therefore, Foghorn Therapeutics's EV-to-FCF for today is -1.15.
The historical rank and industry rank for Foghorn Therapeutics's EV-to-FCF or its related term are showing as below:
FHTX'
s EV-to-FCF Range Over the Past 10 Years
Min: -31.37 Med: -0.75 Max: 1.75
Current: -1.15
During the past 6 years, the highest EV-to-FCF of Foghorn Therapeutics was 1.75. The lowest was -31.37. And the median was -0.75.
FHTX's EV-to-FCF is ranked worse than 100% of 386
companies
in the Biotechnology industry
Industry Median: 8.605
vs FHTX: -1.15
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for Foghorn Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Foghorn Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Foghorn Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Foghorn Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Foghorn Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Foghorn Therapeutics's EV-to-FCF falls into.
Foghorn Therapeutics's current Enterprise Value is $119.69 Mil.
Foghorn Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-103.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Foghorn Therapeutics's PE Ratio (TTM) for today is calculated as:
Foghorn Therapeutics's share price for today is $6.18.
Foghorn Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.920.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Foghorn Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Foghorn Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FHTX has been successfully added to your 